inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. 1. males and females who are 12 years of age or older at the time of obtaining consent 2. those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent. 3. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. 4. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. 1. males and females who are 12 years of age or older at the time of obtaining consent 2. those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent. 3. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. 4. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 12 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 12 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 120 hours prior to obtaining consent. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 20 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 20 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. patients who have fevers (37.5 degrees celsius or higher) and/or at least one of the following symptoms of score 2 or higher at a screening test: myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath. patients with a room air oxygen saturation (spo2) of 96% or higher at the time of the screening test.

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 20 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. those who have fever symptoms (37.5 degrees celsius or higher) at the time of screening test. patients who have at least one symptom with a score of 2 or higher among the symptoms of myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath at the time of the screening test. patients with a blood oxygen saturation (spo2) of 96 % or higher during room air inhalation at the time of the screening test

inclusion criteria: persons who meet all of the following criteria will be eligible for this clinical trial. males and females who are 20 years of age or older at the time of obtaining consent those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. those who have fever symptoms (37.5 degrees celsius or higher) at the time of screening test. patients who have at least one symptom with a score of 2 or higher among the symptoms of myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath at the time of the screening test. patients with a blood oxygen saturation (spo2) of 96 % or higher during room air inhalation at the time of the screening test

inclusion criteria: - persons who meet all of the following criteria will be eligible for this clinical trial. 1. males and females who are 20 years of age or older at the time of obtaining consent 2. those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. 3. those who have fever symptoms (37.5 degrees celsius or higher) at the time of screening test. 4. patients who have at least one symptom with a score of 2 or higher among the symptoms of myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath at the time of the screening test. 5. patients with a blood oxygen saturation (spo2) of 96 % or higher during room air inhalation at the time of the screening test

inclusion criteria: - persons who meet all of the following criteria will be eligible for this clinical trial. 1. males and females who are 20 years of age or older at the time of obtaining consent 2. those who are confirmed positive for sars-cov-2 by antigen test or rt-pcr test using specimens (nasopharynx, nasal cavity, oropharynx, or saliva) collected within 72 hours prior to obtaining consent. 3. those who have fever symptoms (37.5 degrees celsius or higher) at the time of screening test. 4. patients who have at least one symptom with a score of 2 or higher among the symptoms of myalgia, sore throat, diarrhea, nausea, vomiting, cough, and shortness of breath at the time of the screening test. 5. patients with a blood oxygen saturation (spo2) of 96 % or higher during room air inhalation at the time of the screening test